ARMATA PHARMACEUTICALS INC (ARMP) Stock News
NYSEARCA:ARMP - NYSE Arca - US04216R1023 - Common Stock - Currency: USD
ARMP Latest News, Press Relases and Analysis
ARMP Soars 72% in a Month Following Infectious Disease Study Success
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 47.37% and 64.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: DTIL
New Strong Sell Stocks for May 8th
ARMP, COLM and EFSI have been added to the Zacks Rank #5 (Strong Sell) List on May 8, 2025.
New Strong Sell Stocks for April 28th
CCS, ARMP and CABO have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2025.
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 5.26% and 26.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ADCT
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of -27.27% and 29.77%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: SGMO
ARMP Stock Earnings: Armata Pharmaceuticals Beats EPS for Q2 2024
ARMP stock results show that Armata Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.
3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge
Discover three high-growth stock picks set for unprecedented surges in the metals, marine transportation, and pharmaceutical industries.
ARMP Stock Earnings: Armata Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
ARMP stock results show that Armata Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
ARMP Stock Earnings: Armata Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
ARMP stock results show that Armata Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Armata Pharmaceuticals gets $25M in financing and new executive chief (NYSE:ARMP)
Biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, Armata Pharmaceuticals (ARMP) enters...
Mentions: INVA
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of all the biggest pre-market stock movers worth reading about on Thursday!
Armata stock surges 15% as inhaled bacterial drug shows promise in lung disorder patients
Armata Pharmaceuticals (ARMP) said its inhaled bacterial infection drug for lung disorder was well-tolerated with a treatment emergent adverse event ((TEAE)) profile similar to placebo...